Cambridge id 5272415

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cambridge id 5272415
• 英文别名: furan-2-yl-(4-methylpiperazin-1-yl)methanone
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD00456329
• 分子量: 194.23
• InChiKey: CIFGWTBVHGSNMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS<br/>[FR] DÉRIVÉS DE 4-(IMIDAZO[1,2-A] PYRIDIN-3-YL)-N-(PYRIDIN-3-YL)PYRIMIDIN-2-AMINE POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS PROLIFÉRATIVES
  申请人：AUCENTRA THERAPEUTICS PTY LTD

  公开号：WO2021072475A1

  公开（公告）日：2021-04-22

  A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of one or more protein kinases selected from CDKs such as CDK2, CDK4, CDK6 and/or CDK9, and/or other protein kinases such as FLT3 and its mutants. The compounds have the general structure I: (I)

  一类新型的杂环芳基化合物，用于预防和/或治疗包括癌症在内的增殖性疾病和症状。这些化合物被认为能够通过抑制细胞增殖来抑制细胞蛋白激酶的活性，所选的蛋白激酶包括CDKs（如CDK2、CDK4、CDK6和/或CDK9）以及其他蛋白激酶，如FLT3及其突变体。这些化合物具有一般结构I：（I）
• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE SPHINGOSINE-1-PHOSPHATE
  申请人：EXELIXIS INC

  公开号：WO2010045580A1

  公开（公告）日：2010-04-22

  This disclosure relates to sphingosine-1 -phosphate (SlP) receptor antagonists, compositions comprising the SlP receptor antagonists and methods for using and processes for making the SlP receptor antagonists. In particularly, this disclosure relates to sphingosine-1 -phosphate 1 (SlPl) receptor antagonists, compositions comprising the SlPl receptor antagonist and methods for using the SlPl receptor antagonist, such as in the treatment of cancer, and processes for making the SlPl receptor antagonists.

  这项披露涉及神经酰胺-1-磷酸(S1P)受体拮抗剂，包括该S1P受体拮抗剂的组合物以及使用和制备该S1P受体拮抗剂的方法。特别是，这项披露涉及神经酰胺-1-磷酸1(S1P1)受体拮抗剂，包括该S1P1受体拮抗剂的组合物以及使用该S1P1受体拮抗剂的方法，例如在癌症治疗中，并且包括制备该S1P1受体拮抗剂的方法。
• DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20140336165A1

  公开（公告）日：2014-11-13

  Provided is a compound having a D-amino acid oxidase (DAAO) inhibitory action, and useful as, for example, a prophylaxis and/or therapeutic agent for schizophrenia or neuropathic pain. The present inventors have studied a compound that inhibits DAAO, and confirm that a dihydroxy aromatic heterocyclic compound has a DAAO inhibitory action, and completed the present invention. That is, the dihydroxy aromatic heterocyclic compound of the present invention has a good DAAO inhibitory action, and can be used as a prophylaxis and/or therapeutic agent for, for example, schizophrenia or neuropathic pain.

  提供的是一种具有D-氨基酸氧化酶（DAAO）抑制作用的化合物，可用作例如精神分裂症或神经病性疼痛的预防和/或治疗剂。本发明人员研究了一种能够抑制DAAO的化合物，并确认一种二羟基芳香杂环化合物具有DAAO抑制作用，并完成了本发明。换言之，本发明的二羟基芳香杂环化合物具有良好的DAAO抑制作用，并可用作例如精神分裂症或神经病性疼痛的预防和/或治疗剂。
• [EN] QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION<br/>[FR] DERIVES DE QUINOXALINE AYANT UNE ACTION INHIBITRICE SUR PARP
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2003007959A1

  公开（公告）日：2003-01-30

  Quinoxaline derivatives provided by this invention are represented by the formula (I): wherein R?1, R2, R3, R4¿ and the ring A are as defined in the specification, and have poly(adenosine 5'-diphaspho-ribose)polymerase (PARP) inhibitory action.

  本发明提供的喹噁啉衍生物由公式(I)表示：其中R?1，R2，R3，R4和环A如规范中所定义，并具有聚腺苷酸5'-二磷酸核糖酶（PARP）抑制作用。
• PYRAZOLOPYRIDINES AND ANALOGS THEREOF
  申请人：Hays David S.

  公开号：US20090318435A1

  公开（公告）日：2009-12-24

  Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, and 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本文介绍了吡唑吡啶-4-胺，吡唑喹啉-4-胺，吡唑萘啉-4-胺和6,7,8,9-四氢吡唑喹啉-4-胺，含有这些化合物的药物组合物，中间体，制备方法以及这些化合物作为免疫调节剂的用途，用于诱导或抑制动物细胞因子生物合成，以及用于治疗包括病毒和肿瘤疾病在内的疾病。